Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $8.44 Consensus PT from Brokerages

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has earned an average rating of "Moderate Buy" from the ten ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $8.44.

A number of analysts have commented on the stock. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Wednesday, May 14th. Citigroup cut their price target on shares of Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Piper Sandler cut their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Truist Financial cut their price target on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Oppenheimer cut their price target on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Cibc World Markets Corp acquired a new stake in shares of Allogene Therapeutics in the 4th quarter worth about $26,000. PAX Financial Group LLC acquired a new stake in shares of Allogene Therapeutics in the 4th quarter worth about $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Allogene Therapeutics in the 1st quarter worth about $28,000. RPO LLC acquired a new stake in shares of Allogene Therapeutics in the 4th quarter worth about $31,000. Finally, Caption Management LLC acquired a new stake in shares of Allogene Therapeutics in the 4th quarter worth about $32,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Allogene Therapeutics Stock Performance

NASDAQ ALLO traded up $0.01 on Thursday, reaching $1.24. The company had a trading volume of 1,772,506 shares, compared to its average volume of 3,278,732. The business has a 50 day moving average of $1.22 and a two-hundred day moving average of $1.58. Allogene Therapeutics has a fifty-two week low of $0.86 and a fifty-two week high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28). Sell-side analysts expect that Allogene Therapeutics will post -1.28 EPS for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).